The clinical significance of serum VEGF C, VEGF D and sVEGFR2 concentration in lung cancer

W. Naumnik, T. Izycki, M. Ossolinska, E. Chyczewska (Bialystok, Poland)

Source: Annual Congress 2007 - Diagnosis and prognosis in thoracic oncology
Session: Diagnosis and prognosis in thoracic oncology
Session type: Electronic Poster Discussion
Number: 3198
Disease area: Thoracic oncology

Congress or journal article abstractE-poster

Rating: 0
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
W. Naumnik, T. Izycki, M. Ossolinska, E. Chyczewska (Bialystok, Poland). The clinical significance of serum VEGF C, VEGF D and sVEGFR2 concentration in lung cancer. Eur Respir J 2007; 30: Suppl. 51, 3198

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.
You must Login to comment this presentation.


Related content which might interest you:
Clinical significance of serum osteopontin levels in lung cancer
Source: Annual Congress 2012 - New biomarkers for lung cancer
Year: 2012

Pre-operative levels of serum vascular endothelial growth factor A (VEGF-A), C (VEGF-C) and D (VEGF-D) in non-small cell lung cancer (NSCLC). Preliminary report
Source: Annual Congress 2008 - Management, quality aspects and prognosis in thoracic oncology
Year: 2008


Clinical significance of serum survivin, MGB-1 and Pref-1 levels during chemotherapy of lung cancer
Source: Annual Congress 2009 - Biological and clinical markers in lung cancer
Year: 2009

The clinical significance of serum osteoprotegerin (OPG) and pro-gastrin-releasing peptide (ProGRP) concentrations in lung cancer
Source: Eur Respir J 2004; 24: Suppl. 48, 318s
Year: 2004

The prognostic value of serum epidermal growth factor receptor (EGFR) levels in patients with non-small cell lung cancer
Source: Eur Respir J 2004; 24: Suppl. 48, 674s
Year: 2004

Serum levels of angiopoietin-1, angiopoietin-2 and their receptor- Tie-2 in patients with non small cell lung cancer during chemotherapy
Source: Annual Congress 2008 - Biology and prognosis in thoracic oncology
Year: 2008


The clinical significance of serum interleukin 18 concentration in lung cancer
Source: Eur Respir J 2003; 22: Suppl. 45, 394s
Year: 2003

The neoadjuvant therapy of NSCLC down-regulates serum levels of growth factors (VEGF, bFGF, TGF-beta) with no effect on apoptosis (CD95L) and local tumour invasiveness markers (TIMP-1)
Source: Eur Respir J 2006; 28: Suppl. 50, 386s
Year: 2006

Serum levels of vascular endothelial growth factor in lung cancer patients
Source: Eur Respir J 2004; 24: Suppl. 48, 77s
Year: 2004

Clinical significance of serum adipokines levels in lung cancer
Source: Annual Congress 2009 - Biological and clinical markers in lung cancer
Year: 2009

A serum level of IGF-I, IGF-II and IGFBP-3 in patients with small cell lung cancer (SCLC) during chemotherapy
Source: Eur Respir J 2006; 28: Suppl. 50, 86s
Year: 2006

Prognostic significance of plasma D-dimer (DD) in lung cancer
Source: Eur Respir J 2002; 20: Suppl. 38, 72s
Year: 2002

A serum level of IGF-I and IGFBP-3 in patients with lung cancer during chemotherapy
Source: Eur Respir J 2005; 26: Suppl. 49, 329s
Year: 2005

Prognostic value of il-6 and TNF-alfa serum concentration in advanced non-small lung cancer patients
Source: Eur Respir J 2003; 22: Suppl. 45, 251s
Year: 2003

IGF-I and IGFBP-3 concentrations in the blood serum and lung cancer risk
Source: Annual Congress 2007 - Biology of thoracic malignancies
Year: 2007


Expression of vascular endothelial growth factor (VEGF) and its receptors (VEFG-R1-Flt1, VEGF-R2-Flk1) in non small cell lung carcinomas (NSCLC): correlation with lymphangiogenesis and clinical outcome
Source: Annual Congress 2007 - Diagnosis and prognosis in thoracic oncology
Year: 2007


Serum levels of vascular endothelial growth factor (VEGF) are elevated in patients with acute exacerbated COPD
Source: Eur Respir J 2005; 26: Suppl. 49, 350s
Year: 2005

Prognostic significance of three tumor markers (CA125, CEA, and TPA) in lung cancer
Source: Eur Respir J 2002; 20: Suppl. 38, 73s
Year: 2002

Serum levels of interleukin 8 and plasma levels of osteopontin in patients with non-small cell lung cancer during chemotherapy
Source: Annual Congress 2011 - Instructive clinical aspects of lung cancer
Year: 2011

Increased vascular-endothelial growth factor a (VEGF-A) expression and response to angiogenesis inhibitor erlotinib in non-small-cell lung cancer (NSCLC) – hint for a new predictive marker?
Source: Annual Congress 2007 - Therapeutic approaches in thoracic oncology
Year: 2007